117 related articles for article (PubMed ID: 36285353)
1. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib.
Vu AT; Akingunsade L; Hoffer K; Petersen C; Betz CS; Rothkamm K; Rieckmann T; Bussmann L; Kriegs M
Head Neck; 2023 Jan; 45(1):147-155. PubMed ID: 36285353
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
[TBL] [Abstract][Full Text] [Related]
4. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
[TBL] [Abstract][Full Text] [Related]
5. Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.
Bußmann L; Hoffer K; von Bargen CM; Droste C; Lange T; Kemmling J; Schröder-Schwarz J; Vu AT; Akingunsade L; Nollau P; Rangarajan S; de Wijn R; Oetting A; Müller C; Böckelmann LC; Zech HB; Berger JC; Möckelmann N; Busch CJ; Böttcher A; Gatzemeier F; Klinghammer K; Simnica D; Binder M; Struve N; Rieckmann T; Schumacher U; Clauditz TS; Betz CS; Petersen C; Rothkamm K; Münscher A; Kriegs M
Int J Cancer; 2021 Sep; 149(5):1166-1180. PubMed ID: 33890294
[TBL] [Abstract][Full Text] [Related]
6. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
8. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
10. Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
Stegeman H; Kaanders JH; Verheijen MM; Peeters WJ; Wheeler DL; Iida M; Grénman R; van der Kogel AJ; Span PN; Bussink J
Mol Cancer; 2013 Nov; 12(1):133. PubMed ID: 24192080
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
12. c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelial-mesenchymal transition.
Lee S; Park S; Ryu JS; Kang J; Kim I; Son S; Lee BS; Kim CH; Kim YS
Exp Biol Med (Maywood); 2023 Mar; 248(6):492-500. PubMed ID: 36527337
[TBL] [Abstract][Full Text] [Related]
13. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Tatarov O; Mitchell TJ; Seywright M; Leung HY; Brunton VG; Edwards J
Clin Cancer Res; 2009 May; 15(10):3540-9. PubMed ID: 19447874
[TBL] [Abstract][Full Text] [Related]
14. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
15. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Congleton J; MacDonald R; Yen A
Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity.
Congleton J; Shen M; MacDonald R; Malavasi F; Yen A
Cell Signal; 2014 Jul; 26(7):1589-97. PubMed ID: 24686085
[TBL] [Abstract][Full Text] [Related]
18. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
19. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
20. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Stabile LP; Egloff AM; Gibson MK; Gooding WE; Ohr J; Zhou P; Rothenberger NJ; Wang L; Geiger JL; Flaherty JT; Grandis JR; Bauman JE
Oral Oncol; 2017 Jun; 69():38-45. PubMed ID: 28559019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
